-transparent.png){kind=logo}
Two patients with relapsing Clostridium difficile diarrhoea following metronidazole and vancomycin therapy were colonised with a non-toxigenic avirulent Clostridium difficile strain given orally in three doses. Both patients appeared to respond without side-effects. Oral bacteriotherapy with a defined nontoxigenic strain of Clostridium difficile would appear to represent an acceptable, alternative and novel way to treat hospitalised patients who relapse with Clostridium difficile diarrhoea after specific antibiotic therapy.
Related Publications
D Seal, and
S P Borriello, and
F Barclay, and
A Welch, and
M Piper, and
M Bonnycastle
November 2023,
Open forum infectious diseases,
D Seal, and
S P Borriello, and
F Barclay, and
A Welch, and
M Piper, and
M Bonnycastle
October 2001,
Molecular and cellular probes,
D Seal, and
S P Borriello, and
F Barclay, and
A Welch, and
M Piper, and
M Bonnycastle
October 1995,
Microbial pathogenesis,
D Seal, and
S P Borriello, and
F Barclay, and
A Welch, and
M Piper, and
M Bonnycastle
May 1994,
FEMS microbiology letters,
D Seal, and
S P Borriello, and
F Barclay, and
A Welch, and
M Piper, and
M Bonnycastle
July 1981,
Medical laboratory sciences,
D Seal, and
S P Borriello, and
F Barclay, and
A Welch, and
M Piper, and
M Bonnycastle
April 2016,
Evidence-based medicine,
D Seal, and
S P Borriello, and
F Barclay, and
A Welch, and
M Piper, and
M Bonnycastle
April 1983,
The Journal of infectious diseases,
D Seal, and
S P Borriello, and
F Barclay, and
A Welch, and
M Piper, and
M Bonnycastle
May 1989,
Lancet (London, England),
D Seal, and
S P Borriello, and
F Barclay, and
A Welch, and
M Piper, and
M Bonnycastle
May 1980,
Journal of clinical microbiology,
D Seal, and
S P Borriello, and
F Barclay, and
A Welch, and
M Piper, and
M Bonnycastle
January 2013,
Semergen,
